BioCentury | Sep 25, 2020
Management Tracks

Lopes-Fernandes to lead BD for Ipsen; plus

...on Oct. 16 as EVP and head of R&D of the Nicox Group and GM of Nicox...
...Pharmaceuticals Inc. (NASDAQ:ALXN), has joined the Patient-Centered Outcomes Research Institute’s board of governors. BC Staff Decibel Therapeutics Ipsen Group Inivata Nicox S.A. Repertoire...
BioCentury | Mar 13, 2020
Product Development

March 12 Quick Takes: WuXi AppTec’s Wuhan site back online; plus SOX relief, AZ, BMS, Nicox-Ocumesion, Tyligand-Context

...to improve progression free survival vs. platinum-based chemotherapy. Nicox getting €15M, study funding from Ocumension Nicox S.A....
...Compound #), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) Merck & Co. Inc. AstraZeneca plc Bristol Myers Squibb Co. Nicox S.A. Context...
BioCentury | Jan 9, 2018
Finance

Stars in China

...to treat mucopolysaccharidosis VII (MPS VII; Sly syndrome) Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) / Nicox S.A....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 3, 2017
Company News

Nicox, Re-Vana partner for sustained-release formulations for IOP

...Ltd. (Belfast, U.K.) partnered to develop Re-Vana's EyeLief drug delivery platform for sustained release of Nicox's...
...the companies said payments by Nicox related to the agreement were not considered material by Nicox...
...platform. Re-Vana Therapeutics Ltd., Belfast, U.K. Nicox S.A. (Euronext:COX), Sophia Antipolis, France Business: Drug delivery, Ophthalmic Jennie Walters Nicox S.A. EyeLief Re-Vana...
BioCentury | Aug 18, 2017
Clinical News

Valeant expects to resolve manufacturing issues after second Vyzulta CRL

...at the Tampa facility." Vyzulta is a nitric oxide (NO)-donating prostaglandin F2-alpha analog. In 2014, Nicox S.A....
...glaucoma and ocular hypertension. Rhopressa is a dual inhibitor of Rho kinase and norepinephrine transporter. Nicox S.A....
...Quebec Product: Vyzulta latanoprostene bunod (formerly BOL-303259-X , NCX 116 , Vesneo) Business: Ophthalmic Alex Himes latanoprostene bunod Vyzulta Nicox S.A. Valeant...
BioCentury | Aug 11, 2017
Clinical News

Valeant gets second CRL for Vyzulta

...first CRL was issued in July 2016 (see BioCentury, Aug. 1, 2016 ). In 2014, Nicox S.A....
...28, 2018 PDUFA date. Rhopressa is a dual inhibitor of Rho kinase and norepinephrine transporter. Nicox S.A....
...Vyzulta latanoprostene bunod (formerly BOL-303259-X , NCX 116 , Vesneo) Business: Ophthalmic Alex Himes latanoprostene bunod Vyzulta Bausch + Lomb Nicox S.A. Valeant...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Neurocrine Biosciences Inc. (NASDAQ:NBIX) / AbbVie Inc. (NYSE:ABBV) Elagolix Uterine fibroids Ph III data YE17 Nicox S.A....
BioCentury | Jul 7, 2017
Finance

Onward and upward

...lateral sclerosis (ALS) Neurocrine Biosciences Inc. (NASDAQ:NBIX) FDA approves Ingrezza valbenazine to treat tardive dyskinesia Nicox S.A....
BioCentury | Jun 2, 2017
Clinical News

FDA approves Nicox’s Zerviate for ocular itching

...for Zerviate cetirizine (AC-170) to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's...
...an NDA on March 8 (see BioCentury, Oct. 17, 2016 & March 13, 2017 ). Nicox...
...the antihistamine Zyrtec . Nicox S.A. (Euronext:COX), Sophia Antipolis, France Product: Zerviate cetirizine (AC-170) Business: Inflammation Alicia Parker AC-170 Zerviate Nicox S.A. Histamine...
Items per page:
1 - 10 of 531
BioCentury | Sep 25, 2020
Management Tracks

Lopes-Fernandes to lead BD for Ipsen; plus

...on Oct. 16 as EVP and head of R&D of the Nicox Group and GM of Nicox...
...Pharmaceuticals Inc. (NASDAQ:ALXN), has joined the Patient-Centered Outcomes Research Institute’s board of governors. BC Staff Decibel Therapeutics Ipsen Group Inivata Nicox S.A. Repertoire...
BioCentury | Mar 13, 2020
Product Development

March 12 Quick Takes: WuXi AppTec’s Wuhan site back online; plus SOX relief, AZ, BMS, Nicox-Ocumesion, Tyligand-Context

...to improve progression free survival vs. platinum-based chemotherapy. Nicox getting €15M, study funding from Ocumension Nicox S.A....
...Compound #), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) Merck & Co. Inc. AstraZeneca plc Bristol Myers Squibb Co. Nicox S.A. Context...
BioCentury | Jan 9, 2018
Finance

Stars in China

...to treat mucopolysaccharidosis VII (MPS VII; Sly syndrome) Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) / Nicox S.A....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Nov 3, 2017
Company News

Nicox, Re-Vana partner for sustained-release formulations for IOP

...Ltd. (Belfast, U.K.) partnered to develop Re-Vana's EyeLief drug delivery platform for sustained release of Nicox's...
...the companies said payments by Nicox related to the agreement were not considered material by Nicox...
...platform. Re-Vana Therapeutics Ltd., Belfast, U.K. Nicox S.A. (Euronext:COX), Sophia Antipolis, France Business: Drug delivery, Ophthalmic Jennie Walters Nicox S.A. EyeLief Re-Vana...
BioCentury | Aug 18, 2017
Clinical News

Valeant expects to resolve manufacturing issues after second Vyzulta CRL

...at the Tampa facility." Vyzulta is a nitric oxide (NO)-donating prostaglandin F2-alpha analog. In 2014, Nicox S.A....
...glaucoma and ocular hypertension. Rhopressa is a dual inhibitor of Rho kinase and norepinephrine transporter. Nicox S.A....
...Quebec Product: Vyzulta latanoprostene bunod (formerly BOL-303259-X , NCX 116 , Vesneo) Business: Ophthalmic Alex Himes latanoprostene bunod Vyzulta Nicox S.A. Valeant...
BioCentury | Aug 11, 2017
Clinical News

Valeant gets second CRL for Vyzulta

...first CRL was issued in July 2016 (see BioCentury, Aug. 1, 2016 ). In 2014, Nicox S.A....
...28, 2018 PDUFA date. Rhopressa is a dual inhibitor of Rho kinase and norepinephrine transporter. Nicox S.A....
...Vyzulta latanoprostene bunod (formerly BOL-303259-X , NCX 116 , Vesneo) Business: Ophthalmic Alex Himes latanoprostene bunod Vyzulta Bausch + Lomb Nicox S.A. Valeant...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...Neurocrine Biosciences Inc. (NASDAQ:NBIX) / AbbVie Inc. (NYSE:ABBV) Elagolix Uterine fibroids Ph III data YE17 Nicox S.A....
BioCentury | Jul 7, 2017
Finance

Onward and upward

...lateral sclerosis (ALS) Neurocrine Biosciences Inc. (NASDAQ:NBIX) FDA approves Ingrezza valbenazine to treat tardive dyskinesia Nicox S.A....
BioCentury | Jun 2, 2017
Clinical News

FDA approves Nicox’s Zerviate for ocular itching

...for Zerviate cetirizine (AC-170) to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's...
...an NDA on March 8 (see BioCentury, Oct. 17, 2016 & March 13, 2017 ). Nicox...
...the antihistamine Zyrtec . Nicox S.A. (Euronext:COX), Sophia Antipolis, France Product: Zerviate cetirizine (AC-170) Business: Inflammation Alicia Parker AC-170 Zerviate Nicox S.A. Histamine...
Items per page:
1 - 10 of 531